Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the People’s Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, diabetes, and cardiovascular, as well as gastrointestinal area. Its principal products include Mailingda, a category 1.1 drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Afatinib Dimaleate, Sunitinib Malate, Oulanning, Ameining, Ailanning, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, Fulairui, Ruibote, Zexin, Ruiyisheng, Empagliflozin, and Saxagliptin, which are generic drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Viela Bio, Inc. to develop and commercialize inebilizumab for the treatment of autoimmune diseases and hematologic cancers; and strategic collaboration and license agreement with EQRx, INC. to research, develop, manufacture, and commercialize Almonertinib. The company also has a collaboration with Silence Therapeutics plc to develop siRNAs for three undisclosed targets leveraging Silence’s mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People’s Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.